CALT - Calliditas Therapeutics expands license pact with Everest Medicines

Calliditas Therapeutics (NASDAQ:CALT) has expanded its licensing agreement with Everest Medicines II Limited to extend the territory covered to include South Korea for an upfront payment of $3M as well as additional payments and royalties related to future potential approvals and commercialisation of Nefecon in South Korea. Both parties entered into a license agreement in 2019 to develop and commercialize Nefecon in Greater China and Singapore for the chronic autoimmune kidney disease IgA Nephropathy.

For further details see:

Calliditas Therapeutics expands license pact with Everest Medicines